Abstract:Gingival matrix haemorrhage (GMH) and intraventricular haemorrhage (IVH) are major neonatal disorders causing white matter damage (WMI) and neurological impairments in surviving neonates. Preclinical and clinical IVH research has advanced our understanding of the mechanisms driving IVH-induced WMI, including negative effects on oligodendrocyte progenitor cells (OPCs) and blood-generated axons, especially iron and thrombin.Right now, rehabilitation is the sole therapy option. As a result, new treatments must be developed faster to boost these neonates' outcomes. The most promising therapies in IVH124,147,151 infants are blood clot clearance (DRIFT or endoscopic lavage), early intervention (ELVIS), and stem cell transplantation.However, several barriers must be overcome before the findings of this research can be utilized in clinical practice, as both surgical intervention and intraventricular injection have inherent hazards and adverse effects. Brain damage is projected to be decreased by thorough neuro-endoscopic ventricular lavage surgery, and the optimal distribution strategy for stem cells is projected to enhance their therapeutic advantages. Therapy must begin before scarring and permanent damage develop in neonates with IVH, so determining the appropriate treatment window is critical for success.DRIFT clinical research was carried out in newborns with IVH at a median age of 20 days, and some improvements were found, but not as many as expected147.The median age of intervention in ELVIS was 9 days, leading to the lowest ventriculoperitoneal shunt rate observed in neonates with IVH to date and superior results at 2 years111. Nevertheless, prudence is suggested since early surgery may worsen IVH and aggravate damage.Several mechanism-targeted therapies were explored in preclinical animals. Oral or intramuscular thyroxine or celecoxib appear to be the most promising therapy in animal studies, as these drugs were previously granted to humans by the FDA, are straightforward to give and have low adverse-effect profiles. However, iron chelators or anti-thrombin treatment may be poorly tolerated and associated with significant adverse effects.Because the population of people with IVH is so different, a tailored approach to therapy selection may be needed. Blood clot removal, for example, is suitable for babies with grade III IVH but not isolated PVHI. Similarly, regenerative treatments and agents that reduce inflammation and oxidative stress in the brain (such as celecoxib, antioxidants, thyroxine, and stem cells) are likely to be most effective in infants with moderate to severe IVH, while the risk of side effects may limit their use in infants with IVH grade. Other frequent concerns in premature neonates include severe respiratory distress syndrome, low blood pressure, infection, patent ductus arteriosus, and low platelet levels, all of which may delay treatment. Despite these hurdles, feasible therapeutic solutions for neonates with IVH do not seem too far away.

Mesenchymal stem cells transplantation for neuroprotection in preterm infants with severe intraventricular hemorrhage

Human Neural Stem Cell Grafts Modify Microglial Response and Enhance Axonal Sprouting in Neonatal Hypoxic–Ischemic Brain Injury

Thrombin Preconditioning Improves the Therapeutic Efficacy of Mesenchymal Stem Cells in Severe Intraventricular Hemorrhage Induced Neonatal Rats

Umbilical cord-derived mesenchymal stem cell therapy for neurological disorders via inhibition of mitogen-activated protein kinase pathway-mediated apoptosis.

Improvement of human umbilical cord mesenchymal stem cell transplantation on glial cell and behavioral function in a neonatal model of periventricular white matter damage.

Thrombin Preconditioning Enhances Therapeutic Efficacy of Human Wharton's Jelly-Derived Mesenchymal Stem Cells in Severe Neonatal Hypoxic Ischemic Encephalopathy

Hypothermia Augments Neuroprotective Activity of Mesenchymal Stem Cells for Neonatal Hypoxic-Ischemic Encephalopathy

Human Placenta-Derived Mesenchymal Stem Cells Improve Neurological Function in Rats with Intrauterine Hypoxic-Ischaemic Encephalopathy by Reducing Apoptosis and Inflammatory Reactions

Preclinical assessment of thrombin-preconditioned human Wharton's jelly-derived mesenchymal stem cells for neonatal hypoxic-ischaemic brain injury

Improving the future of clinical trials and translation of mesenchymal stromal cell therapies for neonatal disorders

Mesenchymal Stromal Cell-Derived Extracellular Vesicles Reduce Neuroinflammation, Promote Neural Cell Proliferation and Improve Oligodendrocyte Maturation in Neonatal Hypoxic-Ischemic Brain Injury

The role of stem cells in the management of neonatal posthemorrhagic hydrocephalus

Therapeutic potential of in utero mesenchymal stem cell (MSCs) transplantation in rat foetuses with spina bifida aperta.

Gingival and intraventricular haemorrhages are severe newborn diseases causing damage to white matter and neurological dysfunction in surviving newborns who can benefit from gene therapy

Reactive microglia and astrocytes in neonatal intraventricular hemorrhage model are blocked by mesenchymal stem cells

Mesenchymal Stem Cells Transplantation in Intracerebral Hemorrhage: Application and Challenges

Human Umbilical Cord Mesenchymal Stem Cells Have Neuroprotective Effect on Neonatal Mouse Periventricular Leukomalacia

[Intracerebral Transplantation of Human Umbilical Cord-Derived Mesenchymal Stem Cells in Neonatal Rat Model of Hypoxic-Ischemic Brain Damage: Protective Effect to Injured Brain].

Recovery of the brain after intraventricular hemorrhage

Mesenchymal Stem Cell (MSC)-Derived Extracellular Vesicles Protect from Neonatal Stroke by Interacting with Microglial Cells

The Neuroprotective Effect of Mesenchymal Stem Cells is Mediated Through Inhibition of Apoptosis in Hypoxic Ischemic Injury